Trial Condition(s):
Coronary artery disease
Coronary vasomotor response after Riociguat Exposure (CORONARIES)
Bayer Identifier:
14550
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.
Inclusion Criteria
- Male and female patients with coronary artery disease
Exclusion Criteria
- Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Investigative Site Boston, United States, 02114 | Contact Us: E-mail: [email protected] Phone: Not Available |
Trial Design
A study to compare the acute coronary vasodilating effects of the sGC stimulator Riociguat (BAY 63-2521) with the nitric oxide donor nitroglycerin in patients with coronary artery disease
Trial Type:
Interventional
Intervention Type:
Drug
Trial Purpose:
Treatment
Allocation:
Non-randomized
Blinding:
Open Label
Assignment:
Single Group Assignment
Trial Arms:
1
Primary Outcome
- The ratio of the coronary blood flow after Riociguat to the corresponding flow observed after adenosine, compared to that after nitroglycerin administrationTimeframe: Within 5 min after completion of the intracoronary Riociguat infusion
Secondary Outcome
- Adverse event collectionTimeframe: Until 30 days after study drug treatment
Additional Information
Copyright © Bayer
Powered by
